Table 2 Induction response and remission rates (%)
From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
| First induction dose | Second induction dose | |||
|---|---|---|---|---|
| Response | Remission | Response | Remission | |
| Conventional care failure | ||||
| Ustekinumab | 55.5 | 34.9 | 64.9 | 44.9 |
| Adalimumab | 54.8 | 45.6 | 43.0 | 28.0 |
| TNF-alpha inhibitor failure | ||||
| Ustekinumab | 33.7 | 18.5 | 41.1 | 18.4 |
| Vedolizumab | 32.7 | 12.9 | 16.0 | 6.8 |